Roschewski M, Hodson D
Haematologica. 2023; 109(2):388-400.
PMID: 37706315
PMC: 10828633.
DOI: 10.3324/haematol.2021.278613.
Ferreri A, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K
Nat Rev Dis Primers. 2023; 9(1):29.
PMID: 37322012
PMC: 10637780.
DOI: 10.1038/s41572-023-00439-0.
Kurz K, Ott M, Kalmbach S, Steinlein S, Kalla C, Horn H
Cancers (Basel). 2023; 15(8).
PMID: 37190213
PMC: 10137297.
DOI: 10.3390/cancers15082285.
Zhu Q, Wang J, Zhang W, Zhu W, Wu Z, Chen Y
Front Genet. 2022; 13:878618.
PMID: 35646048
PMC: 9133733.
DOI: 10.3389/fgene.2022.878618.
Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L
Nat Commun. 2022; 13(1):2558.
PMID: 35538064
PMC: 9091224.
DOI: 10.1038/s41467-022-30050-y.
Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant.
Wu H, Shi J, Luo Y, Yu J, Lai X, Liu L
JAMA Netw Open. 2022; 5(4):e226114.
PMID: 35385089
PMC: 8987901.
DOI: 10.1001/jamanetworkopen.2022.6114.
Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.
Montesinos-Rongen M, Brunn A, Sanchez-Ruiz M, Kuppers R, Siebert R, Deckert M
Cancers (Basel). 2021; 13(24).
PMID: 34944954
PMC: 8699297.
DOI: 10.3390/cancers13246334.
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.
Gao F, Tian L, Shi H, Zheng P, Wang J, Dong F
Front Genet. 2021; 12:677650.
PMID: 34925435
PMC: 8675234.
DOI: 10.3389/fgene.2021.677650.
Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma.
Wirsching H, Weller M, Balabanov S, Roth P
Cancers (Basel). 2021; 13(12).
PMID: 34203062
PMC: 8234854.
DOI: 10.3390/cancers13123073.
TOX as a potential target for immunotherapy in lymphocytic malignancies.
Liang C, Huang S, Zhao Y, Chen S, Li Y
Biomark Res. 2021; 9(1):20.
PMID: 33743809
PMC: 7981945.
DOI: 10.1186/s40364-021-00275-y.
Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.
Lauw M, Lucas C, Ohgami R, Wen K
Diagnostics (Basel). 2020; 10(12).
PMID: 33322508
PMC: 7764608.
DOI: 10.3390/diagnostics10121076.
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.
Gandhi M, Hoang T, Law S, Brosda S, ORourke K, Tobin J
Blood. 2020; 137(11):1468-1477.
PMID: 33202420
PMC: 7976507.
DOI: 10.1182/blood.2020008520.
Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment.
Cai Q, Fang Y, Young K
Transl Oncol. 2019; 12(3):523-538.
PMID: 30616219
PMC: 6371000.
DOI: 10.1016/j.tranon.2018.11.011.
Introduction of novel agents in the treatment of primary CNS lymphoma.
Grommes C, Nayak L, Tun H, Batchelor T
Neuro Oncol. 2018; 21(3):306-313.
PMID: 30423172
PMC: 6380407.
DOI: 10.1093/neuonc/noy193.
Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.
Takashima Y, Sasaki Y, Hayano A, Homma J, Fukai J, Iwadate Y
Oncotarget. 2018; 9(44):27471-27486.
PMID: 29937999
PMC: 6007945.
DOI: 10.18632/oncotarget.25463.
Epidemiology and biology of relapse after stem cell transplantation.
Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C
Bone Marrow Transplant. 2018; 53(11):1379-1389.
PMID: 29670211
PMC: 6282701.
DOI: 10.1038/s41409-018-0171-z.
Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.
Bruno A, Labreche K, Daniau M, Boisselier B, Gauchotte G, Royer-Perron L
Neuro Oncol. 2018; 20(8):1092-1100.
PMID: 29432597
PMC: 6280140.
DOI: 10.1093/neuonc/noy019.
Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia.
Reina-Castillon J, Pujol R, Lopez-Sanchez M, Rodriguez-Santiago B, Aza-Carmona M, Gonzalez J
Blood Adv. 2018; 1(5):319-329.
PMID: 29296947
PMC: 5744036.
DOI: 10.1182/bloodadvances.2016000943.
Biology of CNS lymphoma and the potential of novel agents.
Rubenstein J
Hematology Am Soc Hematol Educ Program. 2017; 2017(1):556-564.
PMID: 29222305
PMC: 6053314.
DOI: 10.1182/asheducation-2017.1.556.
Advances in Pathobiology of Primary Central Nervous System Lymphoma.
Yang X, Liu Y
Chin Med J (Engl). 2017; 130(16):1973-1979.
PMID: 28776551
PMC: 5555133.
DOI: 10.4103/0366-6999.211879.